

## PREVALENCE OF ANTIBIOTIC RESISTANCE AMONG BACTERIA ISOLATES OF LOWER RESPIRATORY TRACT INFECTION IN COPD SHAHREKORD – IRAN, 2005

Reza Imani<sup>1</sup>, Hamid Rouhi<sup>2</sup>, Forouzan Ganji<sup>3</sup>

### ABSTRACT

**Background:** Bacterial infection is one of the several important causes of exacerbations of chronic obstructive pulmonary disease (COPD). Antibiotic resistance has increased in all the major pathogens. The objective of this study was investigate frequency of drug resistance of species from LRTs.

**Methods:** This cross sectional study was performed in Hajar hospital of shahrekord-Iran. Protected brush samples were obtained from the lower respiratory tract by bronchoscopy in both hospitalized and ambulatory 54 COPD patients with exacerbations yield. The in vitro susceptibilities of the isolates to 6 antimicrobial agents were then determined by the broth microdilution test.

**Results:** Among the *S. pneumoniae* isolates tested 5.9% and 94.1% were intermediate and high level resistant to penicillin and ampicillin respectively. 58.8% of isolates were erythromycin resistance. *H. influenzae* isolates were 100% resistance to penicillin and ampicillin.

**Conclusion:** Antibiotics are an important part of the treatment of COPD, suggesting that every effort should be made to conserve sensitivity of antibiotic by using them appropriately.

**KEY WORDS:** COPD, Drug resistance, LRTIs.

Pak J Med Sci May - June 2007 Vol. 23 No. 3 438-440

### INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a chronic, smoking – related inflammatory disorder of the lungs.<sup>1-3</sup> Patients with chronic bronchitis are more susceptible to infections. Mucus hypersecretion, which is the hallmark of chronic bronchitis, is particularly

associated with mortality from an infectious cause.<sup>4</sup>

There is general agreement that the bacterial species most commonly isolated from sputum and lower respiratory tract during acute exacerbations of COPD are nontypable *H. influenzae*, *Streptococcus pneumoniae* and *Moraxella catarrhalis*.<sup>5,6</sup> In recent years, there has been a dramatic rise in antibiotic resistance among common respiratory pathogens. For example before 1987, <1% of pneumococci in the USA demonstrated high-level resistance to penicillin.<sup>7</sup> In 1997 overall penicillin resistance had reached to 43.8%.<sup>8</sup>

Patients with chronic obstructive pulmonary disease are generally subjected to multiple regimens of antimicrobial treatment. It is difficult to decide whether patient characteristics or the risk of antibiotic resistance should influence choice of empiric antibiotic treatment. This study was performed to investigate the

1. Dr. Reza Imani, Infectious & Tropical Diseases Specialist, Associated Professor
  2. Hamid Rouhi, Internist & Pulmonologist, Associated Professor
  3. Forouzan Ganji, Specialist in Community Medicine
- 1-3: Shahrekord University of Medical Sciences, Hajar Hospital, Shahrekord - Iran.

Correspondence:

Dr. Reza Imani,  
E-Mail: imani\_md669@yahoo.com

\* Received for Publication: August 21, 2006

\* Accepted: December 12, 2006

frequency of drug-resistant bacterial species commonly isolated from lower respiratory tract by bronchoscopy.

## MATERIALS AND METHODS

This cross sectional study was performed in Hajar hospital of Shahrekord - Iran in 2005. Protected brush samples were obtained from the lower respiratory tract by bronchoscopy in both hospitalized and ambulatory 54 patients with exacerbations yield. The pathogens collected for study were streptococcus pneumonia, Haemophilus influenzae, Moraxella catarrhalis.

In vitro susceptibility testing was performed by the broth micro dilution test according to guidelines of the National committee for clinical laboratory standards (NCCLS).<sup>9</sup> The MICs of six antimicrobial drugs, penicillin, ampicillin, erythromycin, ciprofloxacin, ceftriaxone, ofloxacin were determined by a standardized microdilution method in 0.1ml volumes of Cation – adjusted Muller – Hinton broth with 5% lysed horse blood. The microdilution plate was inoculated with a disposable inoculator so that the final inoculum was  $5 \times 10^6$  cfu/ml, and was incubated at 37 c for 20 hr.<sup>10</sup> To analyze the factors such as age and sex for acquiring bacterial pneumonia was obtained at the time of patient enrollment in the study. Chi square and independent t test were performed to evaluate that factors.

## RESULTS

Our result showed that culture was positive for 23 (40%) isolates. There were no significant difference between results of culture in variable of age and sex ( $P > 0.05$ ). Table-I

## DISCUSSION

In this study we used bronchoscopy techniques to avoid nasopharyngeal contamination of expectorated sputum. Data from this

study revealed 60% were negative for bacterial culture. We presume that main cause of these infections were viral agents and atypical pathogen. Our data from this study revealed high frequency of pneumococcal penicillin and ampicillin resistance. In 1998 The ANSORP study reported penicillin resistance in Korea almost 80% of all isolates. Pneumococcal drug resistance in Nagasaki, Japan, was also as serious as in Korea.<sup>11</sup> In France, the prevalence of penicillin – resistant *s. pneumoniae* was 53.3% of submitted isolates in 1992. At the same time Germany had low resistance (7.2%).<sup>12</sup>

According to the data from the present study the prevalence rate of erythromycin among *s.pneumonia* was 75% isolates and about ciprofloxacin 29.4% isolates. Reported rates of erythromycin resistance in the western Hemisphere were high in France (58.1%) Spain (57.1%) and the eastern south-central parts of the United States (47%) Reports from Hong Kong and Taiwan showed that 80 to 91% of pneumococcal Isolates were resistant to erythromycin.<sup>13,14</sup>

This study revealed penicillin, ampicillin resistance 100% for *H.influenzae* and *M.catarrhalis*.

In two studies beta-lactamase production was found in 33.4% of *H.influenzae* and 95% of *M. catarrhalis*.<sup>15,16</sup> In Hong Kong investigators demonstrated the high rates of resistance of *s.pneumoniae* isolates to various fluoroquinolones.<sup>14</sup> Recently attention has also been drawn to decreased susceptibility of *S.P* to fluoroquinolones, perhaps reflecting increased use of this class of antibiotic. Use of antibiotics in animal husbandry and agriculture is contributing to the problem. Risk factors for multi drug resistant *S.pneumoniae* includes prior antibiotic use, extremes of age and hospitalization. High rates (>15%) of  $\beta$ -lactamase production were found in the UK,

Table-I: Distribution of antibiotic resistance among bacteria isolates of LRTIs

Pathogens	No. of isolates	Penicillin		Ampicillin		Erythromycin		Ciprofloxacin		Ceftriaxone		Ofloxacin	
		Inter	Resist	Inter	Resist	Inter	Resist	Inter	Resist	Inter	Resist	Inter	Resist
<i>S.Pneumonia</i>	17	5.9	94.1	5.9	94.1	35.3	58.8	17.6	11.8	11.8	5.9	23.5	11.8
<i>H.influenzae</i>	4	0.0	100	0.0	100	50	25	75	25	75	25	75	25
<i>M.catarrhalis</i>	2	0.0	100	100	0.0	100	0.0	0.0	0.0	0.0	0.0	0.0	0.0

France, Belgium and Spain.<sup>12,16</sup> 92.2% of 371 isolates of *M. catarrhalis* collected in Europe in 1998 produced B- lactamase.<sup>12</sup>

According to our data the prevalence of erythromycin-resistant *H. influenzae* is 50% of isolates where as isolates from France showed the same result.<sup>12</sup> Resistance to the Erythromycin is associated with penicillin resistance.<sup>17</sup> Our data showed no fluoroquinolones resistance for isolates of *M. catarrhalis*. Fluoroquinolone resistance was detected in UK, France and Spain.<sup>12,18</sup> Differences in the prevalence of antimicrobial resistance in countries may be due to several factors. Different patterns of antimicrobial usage, which lead to variable selective pressure on resistance, might be one of the primary factors.<sup>19</sup> Other factors could be the distribution of specific serotypes and the spread of resistant clones within certain regions. Respiratory tract infections are the most common indication for antibiotic prescription, accounting for 60% of all scripts in the UK. In Europe, >80% of all LRTI are treated with antibiotics.<sup>19</sup> Healthcare systems around the world are attempting to minimize costs and at the same time improve overall quality of care. As such continuous study for drug resistance and providing guidelines for the use of antibiotics is suggested.

## REFERENCES

1. Woodhead M. Community-acquired pneumonia guidelines an international comparison: A view from Europe. *Chest* 1998;113:1835-75.
2. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian community-acquired pneumonia working group *Clin Infect Dis* 2000;31:383-421.
3. Blasi F. Atypical pathogens and respiratory tract infections. *Eur Respir J* 2004;24:171-81.
4. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. *Eur Respir J* 1995;8:1333-8.
5. Ball P, Tillotson G, Wilson R. Chemotherapy for chronic bronchitis controversies. *La Presse Medicale* 1995;24:189-94.
6. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1992;146:1067-83.
7. Spika JF, Facklam RR, Plikaytis BD. Antimicrobial resistance of *Streptococcus pneumoniae* in the United States, 1979-1987. *J Infect Dis* 1991;163:1273-8.
8. Doern GV, Pfaller MA, Kugler K. Prevalence of antimicrobial resistance among respiratory tract isolates of *Streptococcus pneumoniae* in North America: 1997 results from the SENTRY antimicrobial surveillance program *Clin Infect Dis* 1998 ;27:764-70.
9. National Committee for Clinical Laboratory standards. Performance standards for antimicrobial susceptibility testing; 13th informational supplement 2003;23(1):M100-S13. National committee for clinical laboratory standards, Wayne, Pa.
10. National committee for clinical laboratory standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6, 6th ed, National committee for clinical laboratory standards, Wayne, Pa. 2003.
11. Song JH, Lee NY, Ichiyama S, Yoshida R, Hirakata Y, Fu W. Spread of Drug-Resistant *Streptococcus pneumoniae* in Asian Countries: Asian Network for surveillance of Resistant pathogens (ANSORP) study. *Clinical Infectious Diseases* 1999;28:1206-11.
12. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexaner project. *J Antimicrob Chemother* 2000;(46):TL3-9.
13. Hsueh PR, Teng LJ, Lee LN, Yang PC, Ho SW, Lue HC, et al. Increased prevalence of erythromycin resistance in streptococci substantial upsurge in erythromycin resistant M phenotype in streptococcus pyogenes (1979-1998) but not in streptococcus pneumoniae (1985-1999) in Taiwan. *Microb. Drug Resist* 2002;8:27-33.
14. Lyon IPMDJ, Yung RW, Chan C, Cheng AF. Macrolide resistance in streptococcus pneumoniae in Hong Kong *Antimicrob. Agents chemother* 2001;45:1578-80.
15. Kellner JD, Folrd-Jones EL, Toronto child care center study Group. *Streptococcus pneumoniae* carriage in children attending 59 Canadian child care centers. *Arch Pediatr Adolesc Med* 1999;153:495-502.
16. Boken DJ, Chartrand SA, Goering RV, Kruger R, Harrison CJ. Colonization with penicillin-resistant streptococcus pneumoniae in a child care center. *Pediatr Infect Dis J* 1995;14:879-84.
17. Thornsberry C, Ogilvie P, Kahn J. Surveillance of antimicrobial resistance in streptococcus pneumoniae , Haemophilus influenzae and Moraxella catarrhalis in the United states in 1996-1997 respiratory season. *Lab Invest Group Diang Microbial infect Dis* 1997;29:249-57.
18. Doern GV, Brueggemann AB, Pierce G. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. *Antimicrob Agents chemother* 1996;40:2884-6.
19. Wilson R. Bacteria antibiotics and COPD. *Eur Respir J* 2001;17:995-1007.